Stage III NSCLC Treatment Patterns in Spain: A Population-Based Study of the GOECP-SEOR

Objective: We aimed to provide real-world insights into the management of non-small cell lung cancer stage III (NSCLC-SIII) in Spain. Methods: The GOECP-SEOR group conducted an observational, retrospective, multicenter study in which data from patients diagnosed with NSCLC-SIII treated in Spanish ra...

Descripción completa

Detalles Bibliográficos
Autores: Sosa-Fajardo, P, Martín-Martín, M, Luna-Tirado, J, Lopez-Guerra, JL, Gomis-Sellés, E, Lopez-Mata, M, Valtueña-Peydro, G, Santos-Rodríguez, M, Alvarez-González, AM, Potdevin-Stein, G, Martín-Barrientos, P, Kannemann, A, Farré-Bernado, N, González-Portillo, E, Manso-Lema, A, Rodríguez-Roldán, M, González-Ruiz, MA, Wals-Zurita, A, Linares-Mesa, NA, Garduño-Sánchez, S, Barrionuevo-Castillo, P, Moreno-Fuentes, B, Martos-Alcalde, M, Simon-Silva, P, Peña-Perea, MT, Blanco-Villar, ML, Vera-Barragán, V, Ocanto-Martínez, A, Mateos-Domínguez, M, Vallejo-Ocaña, C, Hernanz-Lucas, R, Castro-Gomez, JE, Peña-Huertas, M, Duque-Santana, V, Zapatero-Ortuño, J, García-Torres, C, Valencia-Nieto, P, Diezhandino-García, P, Eito-Valdovinos, C, Olarte-García, A, Guerrero-Gomez, LL, Sánchez-García, S, Bobo-Jaureguizar, A, Sotoca-Ruiz, A, Vázquez-Barreiro, B, Cameselle-Gallego, G, Flamarique-Andueza, S, Rico-Oses, M, Guijarro-Verdu, M, Montijano-Linde, M, Guzmán-Gomez, L, Bezares-Alarcon, AB, Cigarral-García, C, Moreno-Ceano, P, Serrano-Andreu, J, Murcia-Mejía, M, Pagola-Divasson, M, Casas-Duran, F, Almendros-Blanco, P, Pedraza-Fernández, S, González-Ferreira, JA, Alcántara, P, Couñago, F
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:dnet:r-iibsantpa_::af3ea26e8c1bdfc87ff9613da12ba1cb
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=20722
Access Level:acceso abierto
Palabra clave:non-small cell lung cancer stage III
concurrent chemoradiotherapy
immunotherapy
durvalumab
observational
population-based
real-world study
Descripción
Sumario:Objective: We aimed to provide real-world insights into the management of non-small cell lung cancer stage III (NSCLC-SIII) in Spain. Methods: The GOECP-SEOR group conducted an observational, retrospective, multicenter study in which data from patients diagnosed with NSCLC-SIII treated in Spanish radiotherapy departments (RTDs) were collected. Results: A total of 1505 NSCLC-SIII patients from 35 RTDs from 2018 to 2021 were recruited. A total of 871 patients (57.9%) received concurrent chemoradiotherapy (cCRT), and 390 patients (25.91%) received maintenance durvalumab. The immunotherapy (IT) was well tolerated, with Common Terminology Criteria for Adverse Events (CTCAE) Grade 0-2 toxicity observed in 85% of the patients (295 patients). The median overall survival (OS) was 26 months (95% CI 9.4-Not Reached NR). There was a statistically significant difference when patients were stratified by IT, with a median OS of 40 months (95% CI 22.1-NR) in the IT maintenance cohort compared with 19.4 months (95% CI 7.1-58.1) in the non-IT cohort. Differences were also noted in progression-free survival (PFS), with a median PFS of 20.8 months (95% CI 9.6-NR) in the IT cohort versus 8.4 months (95% CI 3.1-25.1) in the non-IT cohort. These differences remained significant according to the multivariate model (OS: HR 0.45 [95% CI 0.36-0.56], p < 0.001; PFS: HR 0.5 [95% CI 0.42-0.59], p < 0.001). Conclusions: The management of NSCLC-SIII patients can vary, leading to differences in treatment outcomes. The treatment of lung cancer in NSCLC-SIII patients in RTDs across Spain aligns with international guidelines and expert recommendations.

Similares en LA Referencia